Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Cell-active carbazole derivatives as inhibitors of the zika virus protease.

Rassias G, Zogali V, Swarbrick CMD, Ki Chan KW, Chan SA, Gwee CP, Wang S, Kaplanai E, Canko A, Kiousis D, Lescar J, Luo D, Matsoukas MT, Vasudevan SG.

Eur J Med Chem. 2019 Jul 17;180:536-545. doi: 10.1016/j.ejmech.2019.07.007. [Epub ahead of print]

PMID:
31344613
2.

A T164S mutation in the dengue virus NS1 protein is associated with greater disease severity in mice.

Chan KWK, Watanabe S, Jin JY, Pompon J, Teng D, Alonso S, Vijaykrishna D, Halstead SB, Marzinek JK, Bond PJ, Burla B, Torta F, Wenk MR, Ooi EE, Vasudevan SG.

Sci Transl Med. 2019 Jun 26;11(498). pii: eaat7726. doi: 10.1126/scitranslmed.aat7726.

PMID:
31243154
3.

Zika virus nonstructural protein 5 residue R681 is critical for dimer formation and enzymatic activity.

Saw WG, Chan KW, Vasudevan SG, Grüber G.

FEBS Lett. 2019 Jun;593(12):1272-1291. doi: 10.1002/1873-3468.13437. Epub 2019 May 31.

PMID:
31090058
4.

Assessing the utility of antivirals for preventing maternal-fetal transmission of zika virus in pregnant mice.

Watanabe S, Tan NWW, Chan KWK, Vasudevan SG.

Antiviral Res. 2019 Jul;167:104-109. doi: 10.1016/j.antiviral.2019.04.013. Epub 2019 Apr 30.

PMID:
31051186
5.

Antiviral Candidates for Treating Hepatitis E Virus Infection.

Netzler NE, Enosi Tuipulotu D, Vasudevan SG, Mackenzie JM, White PA.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00003-19. doi: 10.1128/AAC.00003-19. Print 2019 Jun.

PMID:
30885901
6.

Stearoyl-CoA desaturase-1 is required for flavivirus RNA replication.

Hishiki T, Kato F, Nio Y, Watanabe S, Wen Tan NW, Yamane D, Miyazaki Y, Lin CC, Suzuki R, Tajima S, Lim CK, Saijo M, Hijikata M, Vasudevan SG, Takasaki T.

Antiviral Res. 2019 May;165:42-46. doi: 10.1016/j.antiviral.2019.03.002. Epub 2019 Mar 7.

PMID:
30853381
7.

Zika Virus NS5 Forms Supramolecular Nuclear Bodies That Sequester Importin-α and Modulate the Host Immune and Pro-Inflammatory Response in Neuronal Cells.

Ng IHW, Chan KW, Tan MJA, Gwee CP, Smith KM, Jeffress SJ, Saw WG, Swarbrick CMD, Watanabe S, Jans DA, Grüber G, Forwood JK, Vasudevan SG.

ACS Infect Dis. 2019 Jun 14;5(6):932-948. doi: 10.1021/acsinfecdis.8b00373. Epub 2019 Mar 19.

PMID:
30848123
8.

Dengue Virus and Zika Virus Serological Cross-reactivity and Their Impact on Pathogenesis in Mice.

Watanabe S, Tan NWW, Chan KWK, Vasudevan SG.

J Infect Dis. 2019 Jan 7;219(2):223-233. doi: 10.1093/infdis/jiy482.

PMID:
30085051
9.

Dengue Antiviral Development: A Continuing Journey.

Low JG, Gatsinga R, Vasudevan SG, Sampath A.

Adv Exp Med Biol. 2018;1062:319-332. doi: 10.1007/978-981-10-8727-1_22. Review.

PMID:
29845542
10.

The Transactions of NS3 and NS5 in Flaviviral RNA Replication.

Tay MYF, Vasudevan SG.

Adv Exp Med Biol. 2018;1062:147-163. doi: 10.1007/978-981-10-8727-1_11. Review.

PMID:
29845531
11.

The Dengue Virus Replication Complex: From RNA Replication to Protein-Protein Interactions to Evasion of Innate Immunity.

Lescar J, Soh S, Lee LT, Vasudevan SG, Kang C, Lim SP.

Adv Exp Med Biol. 2018;1062:115-129. doi: 10.1007/978-981-10-8727-1_9. Review.

PMID:
29845529
12.

Viral Entry and NS1 as Potential Antiviral Drug Targets.

de Silva AM, Rey FA, Young PR, Hilgenfeld R, Vasudevan SG.

Adv Exp Med Biol. 2018;1062:107-113. doi: 10.1007/978-981-10-8727-1_8. Review.

PMID:
29845528
13.

Preclinical Antiviral Testing for Dengue Virus Infection in Mouse Models and Its Association with Clinical Studies.

Watanabe S, Low JG, Vasudevan SG.

ACS Infect Dis. 2018 Jul 13;4(7):1048-1057. doi: 10.1021/acsinfecdis.8b00054. Epub 2018 Jun 1.

PMID:
29756760
14.

Rational Engineering and Characterization of an mAb that Neutralizes Zika Virus by Targeting a Mutationally Constrained Quaternary Epitope.

Tharakaraman K, Watanabe S, Chan KR, Huan J, Subramanian V, Chionh YH, Raguram A, Quinlan D, McBee M, Ong EZ, Gan ES, Tan HC, Tyagi A, Bhushan S, Lescar J, Vasudevan SG, Ooi EE, Sasisekharan R.

Cell Host Microbe. 2018 May 9;23(5):618-627.e6. doi: 10.1016/j.chom.2018.04.004.

15.

Luteolin escape mutants of dengue virus map to prM and NS2B and reveal viral plasticity during maturation.

Peng M, Swarbrick CMD, Chan KW, Luo D, Zhang W, Lai X, Li G, Vasudevan SG.

Antiviral Res. 2018 Jun;154:87-96. doi: 10.1016/j.antiviral.2018.04.013. Epub 2018 Apr 14.

PMID:
29665375
16.

A systematic approach to the development of a safe live attenuated Zika vaccine.

Kwek SS, Watanabe S, Chan KR, Ong EZ, Tan HC, Ng WC, Nguyen MTX, Gan ES, Zhang SL, Chan KWK, Tan JH, Sessions OM, Manuel M, Pompon J, Chua C, Hazirah S, Tryggvason K, Vasudevan SG, Ooi EE.

Nat Commun. 2018 Mar 12;9(1):1031. doi: 10.1038/s41467-018-03337-2.

17.

Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis.

Reid DW, Campos RK, Child JR, Zheng T, Chan KWK, Bradrick SS, Vasudevan SG, Garcia-Blanco MA, Nicchitta CV.

J Virol. 2018 Mar 14;92(7). pii: e01766-17. doi: 10.1128/JVI.01766-17. Print 2018 Apr 1.

18.

NS3 helicase from dengue virus specifically recognizes viral RNA sequence to ensure optimal replication.

Swarbrick CMD, Basavannacharya C, Chan KWK, Chan SA, Singh D, Wei N, Phoo WW, Luo D, Lescar J, Vasudevan SG.

Nucleic Acids Res. 2017 Dec 15;45(22):12904-12920. doi: 10.1093/nar/gkx1127.

19.

18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment response.

Chacko AM, Watanabe S, Herr KJ, Kalimuddin S, Tham JY, Ong J, Reolo M, Serrano RM, Cheung YB, Low JG, Vasudevan SG.

JCI Insight. 2017 May 4;2(9). pii: 93474. doi: 10.1172/jci.insight.93474. eCollection 2017 May 4.

20.

Current Status of Dengue Therapeutics Research and Development.

Low JG, Ooi EE, Vasudevan SG.

J Infect Dis. 2017 Mar 1;215(suppl_2):S96-S102. doi: 10.1093/infdis/jiw423. Review.

21.

Luteolin restricts dengue virus replication through inhibition of the proprotein convertase furin.

Peng M, Watanabe S, Chan KWK, He Q, Zhao Y, Zhang Z, Lai X, Luo D, Vasudevan SG, Li G.

Antiviral Res. 2017 Jul;143:176-185. doi: 10.1016/j.antiviral.2017.03.026. Epub 2017 Apr 5.

PMID:
28389141
22.

Flavivirus RNA transactions from viral entry to genome replication.

Garcia-Blanco MA, Vasudevan SG, Bradrick SS, Nicchitta C.

Antiviral Res. 2016 Oct;134:244-249. doi: 10.1016/j.antiviral.2016.09.010. Epub 2016 Sep 22. Review.

PMID:
27666184
23.

The C-terminal 18 Amino Acid Region of Dengue Virus NS5 Regulates its Subcellular Localization and Contains a Conserved Arginine Residue Essential for Infectious Virus Production.

Tay MY, Smith K, Ng IH, Chan KW, Zhao Y, Ooi EE, Lescar J, Luo D, Jans DA, Forwood JK, Vasudevan SG.

PLoS Pathog. 2016 Sep 13;12(9):e1005886. doi: 10.1371/journal.ppat.1005886. eCollection 2016 Sep.

24.

Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients.

Sung C, Wei Y, Watanabe S, Lee HS, Khoo YM, Fan L, Rathore AP, Chan KW, Choy MM, Kamaraj US, Sessions OM, Aw P, de Sessions PF, Lee B, Connolly JE, Hibberd ML, Vijaykrishna D, Wijaya L, Ooi EE, Low JG, Vasudevan SG.

PLoS Negl Trop Dis. 2016 Aug 10;10(8):e0004851. doi: 10.1371/journal.pntd.0004851. eCollection 2016 Aug.

25.

Novel antiviral activity of bromocriptine against dengue virus replication.

Kato F, Ishida Y, Oishi S, Fujii N, Watanabe S, Vasudevan SG, Tajima S, Takasaki T, Suzuki Y, Ichiyama K, Yamamoto N, Yoshii K, Takashima I, Kobayashi T, Miura T, Igarashi T, Hishiki T.

Antiviral Res. 2016 Jul;131:141-7. doi: 10.1016/j.antiviral.2016.04.014. Epub 2016 May 12.

26.

Novel dengue virus inhibitor 4-HPR activates ATF4 independent of protein kinase R-like Endoplasmic Reticulum Kinase and elevates levels of eIF2α phosphorylation in virus infected cells.

Fraser JE, Wang C, Chan KW, Vasudevan SG, Jans DA.

Antiviral Res. 2016 Jun;130:1-6. doi: 10.1016/j.antiviral.2016.03.006. Epub 2016 Mar 8.

PMID:
26965420
27.

Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy.

Watanabe S, Chan KW, Dow G, Ooi EE, Low JG, Vasudevan SG.

Antiviral Res. 2016 Mar;127:10-9. doi: 10.1016/j.antiviral.2015.12.008. Epub 2016 Jan 13.

PMID:
26794905
28.

Characterization of RyDEN (C19orf66) as an Interferon-Stimulated Cellular Inhibitor against Dengue Virus Replication.

Suzuki Y, Chin WX, Han Q, Ichiyama K, Lee CH, Eyo ZW, Ebina H, Takahashi H, Takahashi C, Tan BH, Hishiki T, Ohba K, Matsuyama T, Koyanagi Y, Tan YJ, Sawasaki T, Chu JJ, Vasudevan SG, Sano K, Yamamoto N.

PLoS Pathog. 2016 Jan 6;12(1):e1005357. doi: 10.1371/journal.ppat.1005357. eCollection 2016 Jan.

29.

Identification of covalent active site inhibitors of dengue virus protease.

Koh-Stenta X, Joy J, Wang SF, Kwek PZ, Wee JL, Wan KF, Gayen S, Chen AS, Kang C, Lee MA, Poulsen A, Vasudevan SG, Hill J, Nacro K.

Drug Des Devel Ther. 2015 Dec 10;9:6389-99. doi: 10.2147/DDDT.S94207. eCollection 2015.

30.

Molecular basis for specific viral RNA recognition and 2'-O-ribose methylation by the dengue virus nonstructural protein 5 (NS5).

Zhao Y, Soh TS, Lim SP, Chung KY, Swaminathan K, Vasudevan SG, Shi PY, Lescar J, Luo D.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14834-9. doi: 10.1073/pnas.1514978112. Epub 2015 Nov 17.

31.

Structural insight and flexible features of NS5 proteins from all four serotypes of Dengue virus in solution.

Saw WG, Tria G, Grüber A, Subramanian Manimekalai MS, Zhao Y, Chandramohan A, Srinivasan Anand G, Matsui T, Weiss TM, Vasudevan SG, Grüber G.

Acta Crystallogr D Biol Crystallogr. 2015 Nov;71(Pt 11):2309-27. doi: 10.1107/S1399004715017721. Epub 2015 Oct 31.

32.

Animal models for studying dengue pathogenesis and therapy.

Chan KW, Watanabe S, Kavishna R, Alonso S, Vasudevan SG.

Antiviral Res. 2015 Nov;123:5-14. doi: 10.1016/j.antiviral.2015.08.013. Epub 2015 Aug 21. Review.

PMID:
26304704
33.

Flexibility of NS5 Methyltransferase-Polymerase Linker Region Is Essential for Dengue Virus Replication.

Zhao Y, Soh TS, Chan KW, Fung SS, Swaminathan K, Lim SP, Shi PY, Huber T, Lescar J, Luo D, Vasudevan SG.

J Virol. 2015 Oct;89(20):10717-21. doi: 10.1128/JVI.01239-15. Epub 2015 Aug 12.

34.

The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development.

Luo D, Vasudevan SG, Lescar J.

Antiviral Res. 2015 Jun;118:148-58. doi: 10.1016/j.antiviral.2015.03.014. Epub 2015 Apr 2. Review.

PMID:
25842996
35.

Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.

Watanabe S, Chan KW, Wang J, Rivino L, Lok SM, Vasudevan SG.

J Virol. 2015 Jun;89(11):5847-61. doi: 10.1128/JVI.00216-15. Epub 2015 Mar 18.

36.

A crystal structure of the Dengue virus NS5 protein reveals a novel inter-domain interface essential for protein flexibility and virus replication.

Zhao Y, Soh TS, Zheng J, Chan KW, Phoo WW, Lee CC, Tay MY, Swaminathan K, Cornvik TC, Lim SP, Shi PY, Lescar J, Vasudevan SG, Luo D.

PLoS Pathog. 2015 Mar 16;11(3):e1004682. doi: 10.1371/journal.ppat.1004682. eCollection 2015 Mar.

37.

Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.

Li L, Basavannacharya C, Chan KW, Shang L, Vasudevan SG, Yin Z.

Chem Biol Drug Des. 2015 Sep;86(3):255-64. doi: 10.1111/cbdd.12500. Epub 2015 Feb 4.

PMID:
25533891
38.

The C-terminal 50 amino acid residues of dengue NS3 protein are important for NS3-NS5 interaction and viral replication.

Tay MY, Saw WG, Zhao Y, Chan KW, Singh D, Chong Y, Forwood JK, Ooi EE, Grüber G, Lescar J, Luo D, Vasudevan SG.

J Biol Chem. 2015 Jan 23;290(4):2379-94. doi: 10.1074/jbc.M114.607341. Epub 2014 Dec 8.

39.

Suramin inhibits helicase activity of NS3 protein of dengue virus in a fluorescence-based high throughput assay format.

Basavannacharya C, Vasudevan SG.

Biochem Biophys Res Commun. 2014 Oct 24;453(3):539-44. doi: 10.1016/j.bbrc.2014.09.113. Epub 2014 Oct 2.

PMID:
25281902
40.

A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection.

Fraser JE, Watanabe S, Wang C, Chan WK, Maher B, Lopez-Denman A, Hick C, Wagstaff KM, Mackenzie JM, Sexton PM, Vasudevan SG, Jans DA.

J Infect Dis. 2014 Dec 1;210(11):1780-91. doi: 10.1093/infdis/jiu319. Epub 2014 Jun 5.

PMID:
24903662
41.

Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.

Low JG, Sung C, Wijaya L, Wei Y, Rathore APS, Watanabe S, Tan BH, Toh L, Chua LT, Hou Y, Chow A, Howe S, Chan WK, Tan KH, Chung JS, Cherng BP, Lye DC, Tambayah PA, Ng LC, Connolly J, Hibberd ML, Leo YS, Cheung YB, Ooi EE, Vasudevan SG.

Lancet Infect Dis. 2014 Aug;14(8):706-715. doi: 10.1016/S1473-3099(14)70730-3. Epub 2014 May 28.

PMID:
24877997
42.

Interferon-mediated ISG15 conjugation restricts dengue virus 2 replication.

Hishiki T, Han Q, Arimoto K, Shimotohno K, Igarashi T, Vasudevan SG, Suzuki Y, Yamamoto N.

Biochem Biophys Res Commun. 2014 May 23;448(1):95-100. doi: 10.1016/j.bbrc.2014.04.081. Epub 2014 Apr 21.

PMID:
24769207
43.

Evaluation of dengue antiviral candidates in vivo in mouse model.

Watanabe S, Vasudevan SG.

Methods Mol Biol. 2014;1138:391-400. doi: 10.1007/978-1-4939-0348-1_24.

PMID:
24696350
44.

Identification of dengue-specific human antibody fragments using phage display.

Tay MY, Lee CC, Vasudevan SG, Moreland NJ.

Methods Mol Biol. 2014;1138:161-73. doi: 10.1007/978-1-4939-0348-1_11.

PMID:
24696337
45.

Cell-based flavivirus infection (CFI) assay for the evaluation of dengue antiviral candidates using high-content imaging.

Tan KH, Ki KC, Watanabe S, Vasudevan SG, Krishnan M.

Methods Mol Biol. 2014;1138:99-109. doi: 10.1007/978-1-4939-0348-1_7.

PMID:
24696333
46.

Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo.

Rathore AP, Haystead T, Das PK, Merits A, Ng ML, Vasudevan SG.

Antiviral Res. 2014 Mar;103:7-16. doi: 10.1016/j.antiviral.2013.12.010. Epub 2013 Dec 31.

PMID:
24388965
47.

Identification and molecular characterization of human antibody fragments specific for dengue NS5 protein.

Zhao Y, Moreland NJ, Tay MY, Lee CC, Swaminathan K, Vasudevan SG.

Virus Res. 2014 Jan 22;179:225-30. doi: 10.1016/j.virusres.2013.11.010. Epub 2013 Nov 18.

PMID:
24262074
48.

Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.

Tay MY, Fraser JE, Chan WK, Moreland NJ, Rathore AP, Wang C, Vasudevan SG, Jans DA.

Antiviral Res. 2013 Sep;99(3):301-6. doi: 10.1016/j.antiviral.2013.06.002. Epub 2013 Jun 14.

PMID:
23769930
49.

Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application.

Ichiyama K, Gopala Reddy SB, Zhang LF, Chin WX, Muschin T, Heinig L, Suzuki Y, Nanjundappa H, Yoshinaka Y, Ryo A, Nomura N, Ooi EE, Vasudevan SG, Yoshida T, Yamamoto N.

PLoS Negl Trop Dis. 2013 Apr 25;7(4):e2188. doi: 10.1371/journal.pntd.0002188. Print 2013.

50.

Supplemental Content

Loading ...
Support Center